This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
British Journal of Cancer Open Access 02 March 2018
-
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
Blood Cancer Journal Open Access 15 May 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP . The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115: 727–738.
Hideshima H, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL et al. Small molecule inhibition of proteasome and aggresome function induces synergistic anti-tumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005; 102: 8567–8572.
Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012; 119: 2579–2589.
Raje N, Mahindra A, Vogl D, Voorhees P, Wirk B, Hari P et al. New drug partner for combination therapy in multiple myeloma (MM): development of ACY-1215, a selective histone deacetylase 6 inhibitor alone and in combination with bortezomib or lenalidomide. Haematologica 2013; 98 (S1): 320.
Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004; 101: 540–545.
Dimopoulos M, Jagannath S, Yoon S-S, Siegel D, Lonial S, Hajek R et al. Vantage 088. Vorinostst in combination with bortezomib in patients with relapsed refractory multiple myeloma: results of a global randomized phase 3 trial. Blood 2011; 118: 368–369.
Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 2013; 27 (8): 1707–1714.
Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia 2013; e-pub ahead of print 14 May 2013; doi:10.1038/leu.2013.152.
Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010; 6: 238–243.
Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441–3449.
Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernandez-Lazaro D et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2010; 95: 794–803.
Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D et al. Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple myeloma. Leukemia 2013; e-pub ahead of print 5 August 2013; doi:10.1038/leu.2013.231.
Baradari V, Hopfner M, Huether A, Schuppan D, Scherubl H . Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol 2007; 13: 4458–4466.
Rodrigo-Brenni MC, Foster SA, Morgan DO . Catalysis of lysine 48-specific ubiquitin chain assembly by residues in E2 and ubiquitin. Mol Cell 2010; 39: 548–559.
Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L et al. Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood 2012; 119: 5772–5781.
Acknowledgements
This study was supported by the National Institute of Health Grants (SPORE-P50100707, P01 CA78378, R01 CA50947 (KCA) and P50 CA086355 (RM). KCA is an American Cancer Society Clinical Research Professor.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
TH and NR are consultants for Acetylon Pharmaceuticals. KCA is a member of the advisory committees for Onyx, Celgene, Gilead and Sanofi-Aventis and is a scientific founder of Acetylon and Oncopep. RM has financial interests in SHAPE Pharmaceuticals and Acetylon Pharmaceuticals. He is also the inventor on IP licensed to these two entities. RM’s interests were reviewed and are managed by the Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. PGR is a member of advisory board for Celgene, Millennium, Johnson & Johnson, Novartis and Keryx. Other authors declare no competing financial interests.
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Hideshima, T., Mazitschek, R., Santo, L. et al. Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors. Leukemia 28, 457–460 (2014). https://doi.org/10.1038/leu.2013.301
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.301
This article is cited by
-
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
British Journal of Cancer (2018)
-
Histone deacetylase inhibitors in multiple myeloma: from bench to bedside
International Journal of Hematology (2016)
-
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
Blood Cancer Journal (2015)